14 July 2022

Communicable Diseases Gout

Encouraging real-world data for JAKi and cancer

23 June 2022

Biologics Gout PBAC

‘Game-changer’ on horizon for alopecia areata

5 May 2022

Analgesics Gout

Alopecia hope in common arthritis drug

5 May 2022

COVID-19 Gout PBS Rheumatoid Arthritis Spondyloarthritis

Flare rates low after covid vax

10 March 2022

Ankylosing Spondylitis Gout Juvenile Arthritis Pharmacy Guild of Australia Ross River Virus

Promising findings on steroid-sparing options for PMR and GCA

3 February 2022

COVID-19 Gout Lupus Scleroderma

Updated covid treatment guidelines and immunosuppressed patients

27 January 2022

Gout Research Spondyloarthritis

Real-world data on JAKi and CV outcomes

22 December 2021

COVID-19 Gout

Rheumatology Republic Year in Review

16 December 2021

Gout Spondyloarthritis

JAKi: To cycle or switch?

9 November 2021

Ankylosing Spondylitis Biologics Gout Pharmacy Guild of Australia

What’s on the way for GCA?

28 October 2021

Biologics Gout Research

Spare a thought for the sperm

30 September 2021

Biologics Gout

JAKi debate: the view from across the ditch

23 September 2021

Biologics Gout

Have JAK inhibitors failed to meet their promise?

2 September 2021

Gout PBAC

FDA black box blow for all JAK inhibitors

8 July 2021

Corticosteroids Gastro Gout Rural Spondyloarthritis

Some DMARDs may lower CVD risk in RA patients

1 July 2021

Gout Spondyloarthritis

Anti-JAKs increasingly popular for RA patients